Design Therapeutics reported net income of -$20.16M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & Cost | ||||||||||||||||||||||||||
| Revenue | ||||||||||||||||||||||||||
| Interest income | ||||||||||||||||||||||||||
| Interest Income - Total | 3.29M | 3.25M | 3.21M | 3.04M | 2.70M | 2.49M | 2.31M | 2.17M | 2.07M | 2.01M | ||||||||||||||||
| Interest expenses | ||||||||||||||||||||||||||
| Interest ExpensesInterest Expense | 2.21M | 2.27M | 2.64M | 2.54M | 2.74M | 2.27M | 2.19M | 2.40M | 3.22M | |||||||||||||||||
| Interest Income - Net | 1.04M | 0.94M | 0.41M | 0.16M | -0.25M | 0.05M | -0.01M | -0.34M | -1.21M | |||||||||||||||||
| Operating Items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 8.54M | 7.34M | 8.76M | 11.29M | 14.30M | 14.26M | 15.73M | 17.06M | 13.26M | 11.01M | 9.80M | 10.52M | 11.88M | 12.16M | 15.38M | 15.74M | 14.59M | 13.43M | 14.38M | 16.39M | ||||||
| Wages, Salaries and OtherWages | 0.10M | 0.22M | 0.22M | 0.23M | 0.26M | 0.25M | 0.26M | |||||||||||||||||||
| Selling, General & AdministrativeSG&A | 2.80M | 3.79M | 4.61M | 4.34M | 4.89M | 5.14M | 5.92M | 5.53M | 5.57M | 4.11M | 4.60M | 4.53M | 4.37M | 4.54M | 5.04M | 5.83M | 4.72M | 4.74M | 5.33M | 5.79M | ||||||
| Operating ExpensesOpex | 11.34M | 11.13M | 13.37M | 15.64M | 19.19M | 19.39M | 21.65M | 22.60M | 18.82M | 15.12M | 14.40M | 15.04M | 16.25M | 16.69M | 20.42M | 21.57M | 19.31M | 18.17M | 19.71M | 22.18M | ||||||
| Operating IncomeOp. Inc | -11.34M | -11.13M | -13.37M | -15.64M | -19.19M | -19.39M | -21.65M | -22.60M | -18.82M | -15.12M | -14.40M | -15.04M | -16.25M | -16.69M | -20.42M | -21.57M | -19.31M | -18.17M | -19.71M | -22.18M | ||||||
| EBIT | -11.34M | -11.13M | -13.37M | -15.64M | -19.19M | -19.39M | -21.65M | -22.60M | -18.82M | -15.12M | -14.40M | -15.04M | -16.25M | -16.69M | -20.42M | -21.57M | -19.31M | -18.17M | -19.71M | -22.18M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Non Operating Interest Expenses | 2.21M | 2.27M | 2.64M | 2.54M | 2.74M | 2.27M | 2.19M | 2.40M | 3.22M | |||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.01M | -0.24M | -1.08M | -0.99M | -1.55M | 0.51M | 1.37M | -0.02M | 0.72M | 9.26M | 3.29M | 3.25M | 3.21M | 3.04M | 2.70M | 2.49M | 2.31M | 2.17M | 2.07M | 2.01M | ||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.02M | 0.06M | 0.10M | 0.64M | 1.49M | 2.05M | 2.36M | 2.66M | 3.03M | 3.28M | 3.29M | 3.25M | 3.21M | |||||||||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -11.33M | -11.37M | -14.45M | -16.63M | -20.74M | -18.89M | -20.28M | -22.61M | -18.11M | -5.87M | -11.11M | -14.00M | -15.31M | -16.29M | -20.26M | -21.82M | -19.27M | -18.18M | -20.04M | -23.39M | ||||||
| Profit After TaxPAT | -11.32M | -11.30M | -14.34M | -15.99M | -19.25M | -16.84M | -19.29M | -19.95M | -15.79M | -11.84M | -11.33M | -11.79M | -13.04M | -13.65M | -17.71M | -19.08M | -17.00M | -16.00M | -17.64M | -20.16M | ||||||
| Income from Continuing OperationsIncome (Continuing) | -11.33M | -11.37M | -14.45M | -16.63M | -20.74M | -18.89M | -20.28M | -22.61M | -18.11M | -5.87M | -11.11M | -14.00M | -15.31M | -16.29M | -20.26M | -21.82M | -19.27M | -18.18M | -20.04M | -23.39M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -11.33M | -11.37M | -14.45M | -16.63M | -20.74M | -18.89M | -20.28M | -22.61M | -18.11M | -5.87M | -11.11M | -14.00M | -15.31M | -16.29M | -20.26M | -21.82M | -19.27M | -18.18M | -20.04M | -23.39M | ||||||
| Income towards Parent CompanyParent Net Inc | -11.33M | -11.37M | -14.45M | -16.63M | -20.74M | -18.89M | -20.28M | -22.61M | -18.11M | -5.87M | -11.11M | -14.00M | -15.31M | -16.29M | -20.26M | -21.82M | -19.27M | -18.18M | -20.04M | -23.39M | ||||||
| Net Income towards Common StockholdersNet Income | -11.33M | -11.37M | -14.45M | -16.63M | -20.74M | -18.89M | -20.28M | -22.61M | -18.11M | -5.87M | -11.11M | -14.00M | -15.31M | -16.29M | -20.26M | -21.82M | -19.27M | -18.18M | -20.04M | -23.39M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -0.21 | -0.25 | -0.26 | -0.30 | -0.37 | -0.34 | -0.36 | -0.40 | -0.32 | -0.10 | -0.20 | -0.25 | -0.27 | -0.29 | -0.36 | -0.38 | -0.34 | -0.32 | -0.33 | -0.37 | ||||||
| EPS (Diluted) | -0.21 | -0.25 | -0.26 | -0.30 | -0.37 | -0.34 | -0.36 | -0.40 | -0.32 | -0.10 | -0.20 | -0.25 | -0.27 | -0.29 | -0.36 | -0.38 | -0.34 | -0.32 | -0.33 | -0.37 | ||||||
| Shares Outstanding | 55.16M | 45.94M | 55.51M | 55.67M | 55.78M | 55.71M | 55.91M | 55.95M | 55.99M | 55.98M | 56.49M | 56.56M | 56.62M | 56.59M | 56.76M | 56.86M | 56.95M | 57.33M | 61.43M | 62.51M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 55.16M | 45.94M | 55.51M | 55.67M | 55.78M | 55.71M | 55.91M | 55.95M | 55.99M | 55.98M | 56.49M | 56.56M | 56.62M | 56.59M | 56.76M | 56.86M | 56.95M | 57.33M | 61.43M | 62.51M | ||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 55.22M | 45.94M | 55.62M | 55.72M | 55.84M | 55.90M | 55.92M | 55.98M | 56.00M | 56.47M | 56.49M | 56.62M | 56.62M | 56.75M | 56.77M | 56.95M | 56.96M | 60.40M | 62.44M | 62.58M | ||||||
| EBITDA | -11.34M | -11.13M | -13.37M | -15.64M | -19.19M | -19.39M | -21.65M | -22.60M | -18.82M | -15.12M | -14.40M | -15.04M | -16.25M | -16.69M | -20.42M | -21.57M | -19.31M | -18.17M | -19.71M | -22.18M |